Chitosan a promising safe and immune-enhancing adjuvant for intranasal vaccines

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 3, 2014, Pages 797-807

  Smith, Alan ^a   Perelman, Michael ^a   Hinchcliffe, Michael ^b  

^a Albert Einstein Centre   (United Kingdom)

^b Paracelsis Ltd   (United Kingdom)

Author keywords

Adjuvant; Avian influenza; Chitosan; Diphtheria; Intranasal; Mucosa; Norovirus; Safety; Vaccine

Indexed keywords

AVIAN INFLUENZA VACCINE; CHITOSAN; CHITOSAN GLUTAMATE; COPOLYMER; DIPHTHERIA VACCINE; IMMUNOLOGICAL ADJUVANT; NOROVIRUS VACCINE; NORWALKVLP; PLACEBO; UNCLASSIFIED DRUG; VIRUS VACCINE; VACCINE;

AVIAN INFLUENZA; CLINICAL EFFECTIVENESS; CROSS REACTION; DIPHTHERIA; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE PAIN; MASS IMMUNIZATION; NASAL DISCHARGE; NASAL DISCOMFORT; NASAL PRURITUS; NASAL STUFFINESS; NONHUMAN; NOROVIRUS INFECTION; NOSE DISEASE; NOSE PAIN; PHYSICAL CHEMISTRY; POWDER; REVIEW; SNEEZING; TREATMENT RESPONSE; VACCINE PRODUCTION; CLINICAL TRIAL (TOPIC); DRUG SCREENING; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; CHITOSAN; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; VACCINES;

EID: 84898416140     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.27449     Document Type: Review

References (65)

1. WHO. Department of Immunization, Vaccines and Biologicals, IVB Strategic plan 2010-15. Draft 24 March 2010. Obtained from: www.who.int/entity/ immunization/.../IVB-SP-2010-15-final-Ver.pdf [Accessed 23 July 2012]
2. Schijns VEJC. Immunological concepts of vaccine adjuvant activity - commentary. Curr Opin Immunol 2000; 12:56-463; http://dx.doi.org/10.1016/S0952- 7915(00)00120-5
3. Amorij J-P, Kersten GFA, Saluja V, Tonnis WF, Hinrichs WLJ, Slütter B, Bal SM, Bouwstra JA, Huckriede A, Jiskoot W. Towards tailored vaccine delivery: needs, challenges and perspectives. J Control Release 2012; 161:363-76; PMID:22245687; http://dx.doi.org/10.1016/j.jconrel.2011.12.039
4. ASDReports. Stakeholder opinions: vaccine administration technologies-beyond needles. Report code: ASDR-1755. 2009. Published by Datamonitor Healthcare.
5. Miller MA, Pisani E. The cost of unsafe injections. Bull World Health Organ 1999; 77:808-11; PMID:10593028
6. Jabbal-Gill I, Watts P, Smith A. Chitosan-based delivery systems for mucosal vaccines. Expert Opin Drug Deliv 2012; 9:1051-67; PMID:22708875; http://dx.doi.org/10.1517/17425247.2012.697455
7. Jabbal-Gill I. Nasal vaccine innovation. J Drug Target 2010; 18:771-86; PMID:21047271; http://dx.doi.org/10.3109/1061186X.2010.523790
8. O'Hagan DT. New generation vaccine adjuvants. In: Encyclopedia of Life Sciences (eLS): John Wiley & Sons Ltd, 2007:[doi: 10.1002/9780470015902. a0020177].
9. Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Ben-Efraim S, Gupta CK. Adjuvants - a balance between toxicity and adjuvanticity. Vaccine 1993; 11:293-306; PMID:8447157; http://dx.doi.org/10.1016/0264-410X(93)90190-9
10. Dekker CL, Gordon L, Klein J. Dose optimization strategies for vaccines: the role of adjuvants and new technologies. Report approved at NVAC Meeting February 2008. Obtained from: www.hhs.gov/nvpo/nvac/doseoptimizationstrategies- 200802.doc [Accessed 3 September 2012]
11. Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009; 30:23-32; PMID:19059004; http://dx.doi.org/10.1016/j.it.2008.09.006
12. Rhee JH, Lee SE, Kim SY. Mucosal vaccine adjuvants update. Clin Exp Vaccine Res 2012; 1:50-63; PMID:23596577; http://dx.doi.org/10.7774/cevr.2012.1. 1.50
13. Petrovsky N, Heinzel S, Honda Y, Lyons AB. New-age vaccine adjuvants, friend or foe? BioPharm Int 2 2007, Obtained from:http://www. biopharminternational.com/biopharm/Downstream+Processing/New-Age-Vaccine- Adjuvant s-Friend-or-Foe/ArticleStandard/Article/detail/444996 [Accessed 3 September 2012].
14. Fujihashi K, Koga T, van Ginkel FW, Hagiwara Y, McGhee JR. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 2002; 20:2431-8; PMID:12057597; http://dx.doi.org/10.1016/S0264- 410X(02)00155-X
15. NIAID (U.S. National Institute of Allergy and Infectious Diseases). Safety evaluation of toxin adjuvants delivered intranasally 2001, Obtained from: www.niaid.nih.gov/topics/entericdiseases/Documents/intranasal.pdf [Accessed 13 November 2013].
16. van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 2000; 165:4778-82; PMID:11045998
17. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, Spyr C, Steffen R. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004; 350:896-903; PMID:14985487; http://dx.doi.org/10.1056/NEJMoa030595
18. Stephenson I, Zambon MC, Rudin A, Colegate A, Podda A, Bugarini R, Del Giudice G, Minutello A, Bonnington S, Holmgren J, et al. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J Virol 2006; 80:4962-70; PMID:16641287; http://dx.doi.org/10.1128/ JVI.80.10.4962-4970.2006
19. Pedersen G, Cox R. The mucosal vaccine quandary: intranasal vs. sublingual immunization against influenza. Hum Vaccin Immunother 2012; 8:689-93; PMID:22495121; http://dx.doi.org/10.4161/hv.19568
20. Amidi M, Mastrobattista E, Jiskoot W, Hennink WE. Chitosan-based delivery systems for protein therapeutics and antigens. Adv Drug Deliv Rev 2010; 62:59-82; PMID:19925837; http://dx.doi.org/10.1016/j.addr.2009.11.009
21. Illum L. Nasal drug delivery - recent developments and future prospects. J Control Release 2012; 161:254-63; PMID:22300620; http://dx.doi.org/10.1016/j. jconrel.2012.01.024
22. Dornish M, Hagen A, Hansson E, Pecheur C, Verdier F, Skaugrud Ø. Safety of Protasan™: ultrapure chitosan salts for biomedical and pharmaceutical use. In: Domard A, Roberts GAF, Vårum KM, eds. Advances in Chitin Science, Vol II, Andre Publisher, Lyon, France, 1997: 664-670.
23. Novamatrix. Safety and toxicology of Protasan™ UP chitosans. Product Information Bulletin, 2002. Obtained from: http://www.novamatrix.biz/ Portals/novamat rix/Content/Docs /Technology/PIB- Safety%20and%20Tox%20of%20Protasan%20UP%20chitosan022007.pdf [Accessed: 11 September 2012].
24. Kitozyme SA. (2011). Chitosan GRAS notice. Obtained from: http://www.accessdata.fda.gov/scripts/fcn/gras-notices/GRN000397.pdf [Accessed 11 September 2012]
25. Primex Ingredients ASA. GRAS claim notification: Primex chitosan, 2001 Obtained from: http://www.accessdata.fda.gov/scripts/fcn/gras-notices/grn000073. pdf [Accessed 11 September 2012].
26. Primex EHF. (2005). Shrimp-derived chitosan - GRAS notification, 2005. Obtained from: http://www.accessdata.fda.gov/scripts/fcn/gras-notices/grn000170. pdf [Accessed 11 September 2012].
27. Raafat D, Sahl HG. Chitosan and its antimicrobial potential - a critical literature survey. Microb Biotech 2009, 2:186-201.
28. Atmar RL, Bernstein DI, Harro CD, Al-Ibrahim MS, Chen WH, Ferreira J, Estes MK, Graham DY, Opekun AR, Richardson C, et al. Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med 2011; 365:2178-87; PMID:22150036; http://dx.doi.org/10.1056/NEJMoa1101245
29. Christensen KS, Cohen AE, Mermelstein FH, Hamilton DA, McNicol E, Babul N, Carr DB. The analgesic efficacy and safety of a novel intranasal morphine formulation (morphine plus chitosan), immediate release oral morphine, intravenous morphine, and placebo in a postsurgical dental pain model. Anesth Analg 2008; 107:2018-24; PMID:19020153; http://dx.doi.org/10.1213/ane. 0b013e318187b952
30. El-Kamary SS, Pasetti MF, Mendelman PM, Frey SE, Bernstein DI, Treanor JJ, Ferreira J, Chen WH, Sublett R, Richardson C, et al. Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J Infect Dis 2010; 202:1649-58; PMID:20979455; http://dx.doi.org/10.1086/657087
31. Mills KH, Cosgrove C, McNeela EA, Sexton A, Giemza R, Jabbal-Gill I, Church A, Lin W, Illum L, Podda A, et al. Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a. Infect Immun 2003; 71:726-32; PMID:12540551; http://dx.doi.org/10.1128/IAI.71.2.726-732.2003
32. Read RC, Naylor SC, Potter CW, Bond J, Jabbal-Gill I, Fisher A, Illum L, Jennings R. Effective nasal influenza vaccine delivery using chitosan. Vaccine 2005; 23:4367-74; PMID:15916838; http://dx.doi.org/10.1016/j.vaccine.2005.04.021
33. Roon KI, Soons PA, Uitendaal MP, de Beukelaar F, Ferrari MD. Pharmacokinetic profile of alniditan nasal spray during and outside migraine attacks. Br J Clin Pharmacol 1999; 47:285-90; PMID:10215753; http://dx.doi.org/10.1046/j.1365-2125.1999.00894.x
34. Stoker DG, Reber KR, Waltzman LS, Ernst C, Hamilton D, Gawarecki D, Mermelstein F, McNicol E, Wright C, Carr DB. Analgesic efficacy and safety of morphine-chitosan nasal solution in patients with moderate to severe pain following orthopedic surgery. Pain Med 2008; 9:3-12; PMID:18254761; http://dx.doi.org/10.1111/j.1526-4637.2007.00300.x
35. Brück WM, Slater JW, Carney BF. Chitin and chitosan from marine organisms. In: Kim S.-K, ed. Chitin, Chitosan, Oligosaccharides and Their Derivatives, CRC Press New York, 2011:11-23.
36. Knezevic-Jugovic Z, Petronijevic Z, Smelcerovic A. Chitin and chitosan from microorganisms. In: Kim S.-K, ed. Chitin, Chitosan, Oligosaccharides and Their Derivatives, CRC Press New York, 2011:25-36.
37. Nwe N, Furuike T, Tamura H. Chitin and chitosan from terrestrial organisms. In: Kim S.-K, ed. Chitin, Chitosan, Oligosaccharides and Their Derivatives, CRC Press New York, 2011:3-10.
38. Rinaudo M, Domard A. Solution properties of chitosan. In: Skjak-Bræk G, Anthonsen T, Sandford P eds. Chitin and Chitosan, Sources, Chemistry, Biochemistry, Physical Properties and Applications: Elsevier, 1989:71-86.
39. Roberts GAF. Chitin Chemistry: The Macmillan Press Ltd, London, 1992.
40. Harding S. Characterisation of chitosan-mucin complexes by sedimentation velocity analytical ultracentrifugation. In: Muzzarelli RAA, Peter MG eds. Chitin Handbook. European Chitin Society, 1997:457-466.
41. Morris G, Kök S, Harding S, Adams G. Polysaccharide drug delivery systems based on pectin and chitosan. Biotechnol Genet Eng Rev 2010; 27:257-84; PMID:21415901; http://dx.doi.org/10.1080/02648725.2010.10648153
42. Arca HC, Günbeyaz M, Senel S. Chitosan-based systems for the delivery of vaccine antigens. Expert Rev Vaccines 2009; 8:937-53; PMID:19538118; http://dx.doi.org/10.1586/erv.09.47
43. Baldrick P. The safety of chitosan as a pharmaceutical excipient. Regul Toxicol Pharmacol 2010; 56:290-9; PMID:19788905; http://dx.doi.org/10.1016/j. yrtph.2009.09.015
44. Kean T, Thanou M. Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Deliv Rev 2010; 62:3-11; PMID:19800377; http://dx.doi.org/10. 1016/j.addr.2009.09.004
45. Ebihara K, Schneeman BO. Interaction of bile acids, phospholipids, cholesterol and triglyceride with dietary fibers in the small intestine of rats. J Nutr 1989; 119:1100-6; PMID:2550597
46. Ormrod DJ, Holmes CC, Miller TE. Dietary chitosan inhibits hypercholesterolaemia and atherogenesis in the apolipoprotein E-deficient mouse model of atherosclerosis. Atherosclerosis 1998; 138:329-34; PMID:9690916; http://dx.doi.org/10.1016/S0021-9150(98)00045-8
47. Furda I. Chitin and chitosan - a special class of dietary fiber. In: Spiller GA, ed. CRC Handbook of Dietary Fiber in Human Nutrition, Third Edition, CRC Press, 2001:45-47.
48. Arai K, Kinumaki T, Fujitta T. Toxicity of chitosan. Bull Tokai Reg Fish Res Lab 1968; 56:89-94
49. Gray HC, Hutcheson PS, Slavin RG. Is glucosamine safe in patients with seafood allergy? J Allergy Clin Immunol 2004; 114:459-60; PMID:15341031; http://dx.doi.org/10.1016/j.jaci.2004.05.050
50. Villacis J, Rice TR, Bucci LR, El-Dahr JM, Wild L, Demerell D, Soteres D, Lehrer SB. Do shrimp-allergic individuals tolerate shrimp-derived glucosamine? Clin Exp Allergy 2006; 36:1457-61;; http://dx.doi.org/10.1111/j.1365-2222.2006. 02590.x.
51. Waibel KH, Haney B, Moore M, Whisman B, Gomez R. Safety of chitosan bandages in shell-fish allergic patients. Mil Med 2011; 176:1153-6; PMID:22128651; http://dx.doi.org/10.7205/MILMED-D-11-00150
52. Newman SP, Simpson M, Fisher T, Iqbal K. Quantification of lung deposition and nasal mucociliary clearance for a nasally administered drug formulation containing chitosan. In: Dalby RN, Byron PR, Peart J, Suman JD and Farr SJ eds. Respiratory Drug Delivery IX, Virginia Commonwealth University, Virginia, 2004:617-19.
53. Aspden TJ, Mason JDT, Jones NS, Lowe J, Skaugrud O, Illum L. Chitosan as a nasal delivery system: the effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers. J Pharm Sci 1997; 86:509-13; PMID:9109057; http://dx.doi.org/10.1021/js960182o
54. McNeela EA, O'Connor D, Jabbal-Gill I, Illum L, Davis SS, Pizza M, Peppoloni S, Rappuoli R, Mills KH. A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine 2000; 19:1188-98; PMID:11137256; http://dx.doi.org/10.1016/ S0264-410X(00)00309-1
55. WHO (World Health Organization). The Immunological Basis for Immunization Series: Module 2 - diphtheria update 2009. Obtained from: http://whqlibdoc.who. int/publications/2009/9789241597869-eng.pdf [Accessed 4 July 2013].
56. Mann AJ, Noulin N, Catchpole A, Stittelaar KJ, de Waal L, Veldhuis Kroeze EJB, Hinchcliffe M, Smith A, Montomoli E, Piccirella S, et al. Intranasal H5N1 vaccination, adjuvanted with chitosan derivatives, protects ferrets against highly pathogenic avian influenza intranasal and intratracheal challenge. PLoS ONE (Forthcoming)
57. Allen DJ, Noad R, Samuel D, Gray JJ, Roy P, Iturriza-Gómara M. Characterisation of a GII-4 norovirus variant-specific surface-exposed site involved in antibody binding. Virol J 2009; 6:150; PMID:19781066; http://dx.doi.org/10.1186/1743-422X-6-150
58. Lindesmith L, Moe C, Marionneau S, Ruvoen N, Jiang X, Lindblad L, Stewart P, LePendu J, Baric R. Human susceptibility and resistance to Norwalk virus infection. Nat Med 2003; 9:548-53; PMID:12692541; http://dx.doi.org/10.1038/ nm860
59. Richardson C. Development of vaccines to prevent norovirus acute gastroenteritis. Presented at Phacilitate Vaccine Forum, Barcelona, Spain, June 24, 2009.
60. Richardson C. Product development and clinical plan for a mucosally-delivered Norwalk vaccine. Presented at 4th International Conference on Vaccines for Enteric Diseases (VED), Lisbon, Portugal, April 27, 2007.
61. Richardson C, Tino WT, Foubert T, Sublett R, Steadman BL, Hinchcliffe M, et al. Design and preclinical evaluation of a dry powder intranasal norovirus vaccine. Poster presented at Third International Calicivirus Conference, Cancun, Mexico, November 12, 2007.
62. Wilson-Welder JH, Torres MP, Kipper MJ, Mallapragada SK, Wannemuehler MJ, Narasimhan B. Vaccine adjuvants: current challenges and future approaches. J Pharm Sci 2009; 98:1278-316; PMID:18704954; http://dx.doi.org/10.1002/jps.21523
63. Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 2001; 51:81-96; PMID:11516781; http://dx.doi.org/10.1016/S0169-409X(01)00171-5
64. Zaharoff DA, Rogers CJ, Hance KW, Schlom J, Greiner JW. Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine 2007; 25:2085-94; PMID:17258843; http://dx.doi.org/10.1016/ j.vaccine.2006.11.034
65. Heffernan MJ, Zaharoff DA, Fallon JK, Schlom J, Greiner JW. In vivo efficacy of a chitosan/IL-12 adjuvant system for protein-based vaccines. Biomaterials 2011; 32:926-32; PMID:20965561; http://dx.doi.org/10.1016/j. biomaterials.2010.09.058